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The effects of cancer research participation on patient experience: a mixed-methods analysis
Patient-reported benefits of research participation have been described by study participants; however, many
studies have small sample sizes or are limited to patient groups with poor prognoses. The purpose of this
study was to explore the effects of research participation on patient experience using survey responses from
a large, national sample of cancer patients (N = 66 462) and interviews with breast cancer patients
attending a London trust. Multivariate logistic regression was used to investigate associations between
taking part in research and positive patient experience. Based on our analysis, patients who participated in
research were more likely to rate their overall care and treatment as ‘very good/excellent’ (ORadj:1.64, 95%
CI: 1.53–1.76, P < 0.001) and to describe positive patient experiences, such as better access to non-standard
care, better interactions with staff and being treated as an individual. However, findings from our
interviews indicated that there was no common understanding of what constitutes cancer research and no
clear delineation between research participation and standard care, from the patient perspective. Further
work to explore how participation positively influences patient experience would be useful to develop
strategies to improve care and treatment for all patients regardless of whether or not they choose, or have
the opportunity, to take part in research.
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INTRODUCTION
The UK has one of the highest levels of participation in
cancer research in the world with more than 20% of newly
diagnosed patients participating in a study in 2011
(Department of Health 2012). Taking part in research
benefits the collective patient population by enabling the
continued improvement of cancer care and treatment;
however, direct benefits as a result of being involved in
research have also been described by study participants.
While improved clinical outcomes and quality of life have
been associated with taking part in research (Peppercorn
et al. 2004), most benefits described by participants relate
to aspects of patient experience, for example having access
to the latest treatments, drugs or specialist equipment
that might not otherwise be available (Cox 1999; Kemeny
et al. 2003). Better access to speciality oncologists or allied
health professionals during study-related visits can make
participants feel they are in expert hands, and conse-
quently taking part in research may appear synonymous
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with receiving the best treatment available. Being part of a
research study can also facilitate better coordination of
care due to increased continuity of staff and the involve-
ment of trial managers or study coordinators (Maslin-
Prothero 2000; Moore 2001), creating a sense of safety for
patients by providing a structured and routinised environ-
ment (Agrawal et al. 2006). Closer follow-up and monitor-
ing, in the form of more frequent diagnostic tests, scans
and screens associated with research studies (Hallowell
et al. 2010), may also act as a source of comfort and secu-
rity to participants (Tolmie et al. 2004). Better patient–
staff relationships are often described by patients involved
in studies, perhaps because consultations are less time-
pressured and patients therefore feel they receive more
attention than usual (Hutchison 1998; Maslin-Prothero
2000). This more frequent positive contact with staff and
greater continuity and coordination of care can help
research participants to feel as if they are recognised and
treated as individuals (Maslin-Prothero 2000) and many
patients who take part in research describe feeling special
or privileged because of their involvement and position in
a trial (Cox 1999; Tolmie et al. 2004). Another benefit
described by some research participants is being better
informed about their condition (Nurgat et al. 2005), which
can allow them to feel more in control of their illness and/
or care and treatment.
While the potential benefits of taking part in research
have been described in the literature, many of the
reported studies involve small numbers of patients
(Moore 2001; Nurgat et al. 2005; Catt et al. 2011). Fur-
thermore, these studies are often limited to patient
groups with poor prognoses (i.e. those participating in
phase I/II clinical trials (Hutchison 1998; Cox 1999; Agra-
wal et al. 2006) or palliative care studies (Barnett 2001;
Shipman et al. 2008)) and so their findings may not be
generalisable to the wider cancer patient population. The
National Cancer Patient Experience Survey (NCPES) is a
series of surveys carried out annually on behalf of the
Department for Health (DH) to assess patient experience
in England. In NCPES 2012-13, a new question about
research participation was introduced thereby providing a
unique opportunity to use national survey data to inves-
tigate the effects of research participation on patient
experience among a large sample of cancer patients with
a variety of prognoses. The overall aim of this study was
to explore the effects of research participation on patient
experience using a mixed-methods approach by combin-
ing secondary analysis of a national quantitative data set
with local interviews of breast cancer patients. On the
basis of previous findings from the literature, we hypoth-
esised that patients would have differing views on cancer
research and that those who took part in research would
report more positive experiences.
METHODS
Quantitative data source
Cross-sectional NCPES 2012-13 data collected on behalf
of the DHwas used for secondary analysis in this study. In
January 2013, the survey was sent to the discharge address
of all patients with a primary diagnosis of cancer who
attended an NHS hospital as an inpatient or day case
between 1 September 2012 and 30 November 2012
(Department of Health 2013). Non-responders were sent
two follow-up reminders and, accounting for individuals
known to have died or moved, a 64% response rate was
achieved. The NCPES 2012-13 contained 82 questions in
total; 70 multiple choice and three free text questions
about aspects of patient experience and nine multiple
choice questions about patients’ clinical and demographic
characteristics. Two questions related to research, namely
Q30 ‘Since your diagnosis, has anyone discussed with you
whether you would like to take part in cancer research?’
and Q31 ‘If yes, did you then go on to take part in cancer
research?’ As patients who provided no response to these
research-related questions (n = 2775) could not be
included in our analysis, the data set analysed in this
study contained responses from 66 462 patients attending
155 hospital trusts across England. Methods for categoris-
ing patient, clinical and trust-level factors have been
described elsewhere (Bone et al. 2014). Briefly gender, age,
ethnicity, employment status, long-standing conditions,
time since first treatment and response to treatment were
derived from patients’ responses to survey questions while
tumour group and day case or inpatient status were
extracted from hospital administration records. Hospital
trusts were categorised by foundation status, location
(inside or outside London) and type (large acute, medium
acute, small acute, specialist and teaching). The largest
groups were chosen as reference categories for regression
analysis, with the exception of gender and long-standing
conditions, where men and not having the specific long-
standing condition were used respectively. The character-
istics of patients and the trusts they attended can be found
in Table S1.
Quantitative data analysis
First, relevant published literature was reviewed to
develop a conceptual model of how research participation
may affect cancer patient experience (Fig. 1). With refer-
ence to this model, the 70 multiple choice questions
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related to experiences of care and treatment contained in
NCPES 2012-13 were screened to identify those likely to
be associated with research participation. In total, 29 ques-
tions were selected a priori for further analysis (Table 1).
As the survey was designed to measure cancer patient
experience generally, not all the proposed effects of
research participation had related questions in the data
set; for example, there were no questions on access to lat-
est treatments, remuneration or clinical outcomes.
Given the benefits reported to be associated with research
participation in other studies (see Introduction), it was hy-
pothesised that research participants would be more likely
than non-participants to rate their overall care positively
and to provide positive responses to the other a priori ques-
tions. To investigate this hypothesis, the recently added
question ‘If [research participation was discussed], did you
then go on to take part in cancer research?’ was used to iden-
tify research participants. Patients who had not been offered
the opportunity to participate in research or who had not
taken part were classed as ‘non-participants’. Responses to
the 29 selected survey questions were binarised in accor-
dance with the official survey guidance (Quality Health
2013); for example, for the question ‘Overall, how would
you rate your care?’, excellent and very good responses were
categorised as ‘positive’ and good, fair and poor as ‘not posi-
tive’ (Table S2). Univariate logistic regression was then used
to describe associations between being a research partici-
pant and a positive response to the a priori questions. To
control for confounding, multivariate logistic regression
was subsequently used; patient, clinical and trust-level
characteristics associated with research participation at a
univariate level (P < 0.10) were included in the multivariate
model. All statistical analyses were carried out using STATA
V.12 (StataCorp LP, College Station, Texas, USA).
Figure 1. Models how research participation may affect cancer patient experience and overall rating of care based on the available pub-
lished literature. Similar aspects of care are enclosed in dashed boxes. Questions from the NCPES 2012-13 related to these a priori
aspects of patient experience are indicated in italics and detailed in Table S2. NCPES, National Cancer Patient Experience Survey.
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Qualitative data source and analysis
In-depth interviews were used to explore the experiences
of cancer patients at a large London trust with the aim of
exploring how patient experience may vary across the care
pathway and to develop strategies to improve care and
treatment. Participation was limited to breast cancer
patients (the largest tumour group nationally and at the
trust) as patient experience is known to vary by tumour
group (Quality Health, 2013). In order to be maximally
inclusive, a convenience approach to sampling was taken.
To be eligible for interview, patients had to be ≥18 years of
age and receiving treatment or follow-up care for breast
cancer at the trust. Patients did not have to have partici-
pated in cancer research and there were no other eligibility
restrictions, e.g. ethnicity, prognosis and stage of treat-
ment. All consecutive patients attending outpatient
oncology clinics were informed of the study by a member
Table 1. The effect of research participation on overall rating of care and a priori aspects of patient experience as measured by
questions in the National Cancer Patient Experience Survey 2012-13
OR 95% CI P-value ORadj* 95% CI P-value
Better overall rating of care
70 Overall how would you rate your care? 1.60 1.50–1.72 <0.001 1.64 1.53–1.76 <0.001
Better interactions with staff
9 Test results were explained in an understandable way 1.16 1.11–1.23 <0.001 1.24 1.18–1.31 <0.001
22 It was easy to contact my Clinical Nurse Specialist 1.08 1.03–1.14 0.002 1.16 1.10–1.22 <0.001
23 My Clinical Nurse Specialist listened carefully to me 1.21 1.12–1.31 <0.001 1.29 1.19–1.39 <0.001
24 My Clinical Nurse Specialist gave understandable
answers to my questions
1.21 1.12–1.31 <0.001 1.25 1.15–1.36 <0.001
37 Doctor gave understandable answers to my questions 1.41 1.31–1.51 <0.001 1.49 1.39–1.60 <0.001
39 Doctors didn’t talk in front of me as if I wasn’t there 1.14 1.04–1.25 0.01 1.21 1.13–1.30 <0.001
41 Nurse gives understandable answers to my questions 1.22 1.15–1.30 <0.001 1.26 1.18–1.34 <0.001
43 Nurses didn’t talk in front of me as if I wasn’t there 1.07 0.99–1.14 0.06 1.12 1.05–1.20 0.001
48 I was given enough privacy when discussing my
condition or treatment
1.05 0.98–1.12 0.16 1.16 1.09–1.24 <0.001
49 I was given enough privacy when being examined or treated 1.09 0.98–1.21 0.11 1.23 1.10–1.37 <0.001
52 I was treated with respect and dignity by the doctors,
nurses and other hospital staff
1.06 1.00–1.13 0.06 1.13 1.06–1.21 <0.001
Better informed about their condition and care
6 Staff explained the purpose of the test beforehand 1.34 1.26–1.43 <0.001 1.32 1.24–1.40 <0.001
7 Staff explained what would be done during the test
procedure beforehand
1.33 1.25–1.43 <0.001 1.31 1.22–1.40 0.04
8 I was given written information about the test beforehand 1.50 1.38–1.62 <0.001 1.46 1.33–1.57 <0.001
67 I was given the right amount of information about
my condition and treatment
1.21 1.14–1.29 0.71 1.28 1.20–1.37 <0.001
Better access to specialist staff and diagnostic tests
5 I had a diagnostic test for cancer in the last 12 months 1.06 0.99–1.13 0.08 1.19 1.11–1.28 <0.001
21 I was given the name of a Clinical Nurse Specialist who
would be in charge of my care
1.94 1.80–2.08 <0.001 1.84 1.70–1.98 <0.001
61 I had an appointment with a cancer doctor in the last 12 months 1.92 1.74–2.13 <0.001 1.61 1.44–1.79 <0.001
66 I had treatment from other allied health professionals,
e.g. dietician for my cancer
1.32 1.27–1.38 <0.001 1.17 1.12–1.22 <0.001
Feel ‘like an individual/special/looked after’
16 My views were taken into account when deciding on treatment 1.19 1.13–1.24 <0.001 1.24 1.19–1.30 <0.001
20 I was involved as much as I wanted to be in decisions
about care and treatment
1.28 1.22–1.34 <0.001 1.35 1.29–1.41 <0.001
47 Doctors and nurses asked me what name I prefer to be called by 1.03 0.98–1.08 0.23 1.13 1.08–1.19 <0.001
50 I was able to discuss my worries and fears with staff
during hospital visit
1.15 1.09–1.21 <0.001 1.21 1.15–1.28 <0.001
60 I was given enough emotional support from hospital staff
as an outpatient
1.09 1.03–1.14 <0.001 1.18 1.12–1.24 <0.001
69 I was treated as a whole person rather than ‘a set of cancer symptoms’ 1.04 0.99–1.09 0.16 1.16 1.10–1.22 <0.001
Better coordination of care
62 Doctor had the right documents such as medical notes
at last appointment
1.21 1.09–1.35 0.001 1.29 1.15–1.44 <0.001
65 The different people treating and caring for me worked well together 0.98 0.94–1.02 0.27 1.08 1.03–1.13 0.001
68 I was offered a written assessment and care plan 1.26 1.20–1.32 <0.001 1.30 1.23–1.37 <0.001
*Adjusting for patient, clinical and trust-level factors found to be associated with research participation, i.e. age, ethnicity, having a
long-standing illness, tumour group, time since first treatment and trust type.
Significant results highlighted in bold.
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of the research team and the study was also advertised in
chemotherapy and radiotherapy suites using posters and
leaflets. All eligible women who volunteered to partici-
pate in the study were offered an interview. In total, 26
in-depth interviews were conducted between September
2012 and February 2013.
During the interviews, the topic of cancer research
was introduced using the NCPES question, ‘Since your
diagnosis, has anyone discussed with you whether you
would like to take part in cancer research?’ To allow
direct comparison of patients’ interview responses with
data from NCPES 2012-13, the interviewer did not
define ‘cancer research’, instead patients were free to
interpret the question based on their beliefs as to what
constituted research. Patients’ attitudes to cancer
research, reasons for participating, what taking part had
involved and the effects of research participation on
experiences of care and treatment were then explored.
Interviews lasted 50–70 min and were recorded and
audio-transcribed. Transcripts were then examined itera-
tively and relevant data related to research participation
coded using Nvivo software. The study had ethical
approval (City & East REC: 12/LO/0685) and all local
NHS research permissions.
RESULTS
Does research participation affect patients’ rating of care
and other aspects of their experience?
Overall, 19.1% (n = 12 682) of NCPES 2012-13 respondents
reported that they had participated in cancer research.
Analysis of their survey responses indicates that patients
who participated in research were more likely than those
that did not to rate their overall care as excellent or very
good (OR: 1.60, 95%CI: 1.50–1.72, P < 0.001). This associa-
tion remained even after patient, clinical and trust-level
factors associated with research participation (i.e. age, eth-
nicity, having a long-standing illness, tumour group, time
since first treatment and trust type) were controlled for
(ORadj: 1.64, 95% CI: 1.53–1.76, P < 0.001). Adjusting for
confounding factors, all of the other a priori questions were
also found to be positively associated with research partici-
pation (Table 1). Research participants were more likely to
report feeling informed about their care and condition and
that they were treated like an individual. Research partici-
pants also reported better interactions with staff, coordina-
tion of care and access to specialist staff and diagnostic
tests. For example, a greater proportion had treatment from
an allied health professional for their cancer (33.3% of
research participants vs. 27.4% of non-participants,
P < 0.001) and patients who took part in research were
almost twice as likely to have been assigned a CNS (ORadj:
1.84, 95%CI: 1.70–1.98, P < 0.001).
Characteristics of interview participants
Of the 26 women we interviewed, 18 had been asked if
they would like to participate in cancer research and 10
reported that they had subsequently taken part in a
research study. One woman was unsure if she had partici-
pated in research or not. Participants ranged in age from 38
to 79 years (median: 58.7 years) and most were White
(n = 19). The majority of women were being treated for
first occurrences of breast cancer (n = 20) and began treat-
ment less than 5 years ago (n = 18).
What does research participation mean to cancer
patients?
Patients’ responses to the question ‘Since your diagnosis,
has anyone discussed with you whether you would like to
take part in cancer research?’ indicated that there was sig-
nificant variation in individuals’ interpretation of what
constituted cancer research. For some, it was synonymous
with participating in a clinical trial, while for others it had
a broader meaning encompassing local service improve-
ment surveys, donation of biological samples and the
interview conducted as part of our study.
What, for being in trials for treatment and things
like that? [Participant 1]
They just keep a sample of my genetics. Then what-
ever research they do in terms of what comes out,
that’s a sample that they can use. [Participant 2]
Someone talked to me about [the service], like what
you’re doing. [Participant 3]
Participation in cancer research differed among these
women. One woman described making great efforts to par-
ticipate in a study that required 6-monthly bone marrow
donations over a 7-year period, while others attendedmulti-
ple additional appointments for heart screening while
undergoing chemotherapy treatment. Other women pre-
sented their contribution to research in a way that sug-
gested it required little additional effort on their part. One
woman described how she was participating in a trial to
compare having 6 with 12 months of Herceptin treatment.
She had been assigned to the standard treatment group of
12 months and took this to mean that she was not doing
anything she would not be doing otherwise. Another
woman who had been randomised to the control arm of an
intervention study giving her standard care did not consider
that she participated in research at all. Several women
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described how, during a routine biopsy, additional tissue
was removed and would later be used for research purposes
or how additional blood was collected during standard pre-
chemotherapy tests as part of a study to identify biological
predictors of side effects. In this way, the boundaries
between research participation and standard treatment
were often not clearly differentiated by patients.
When (I) had the biopsy, they said they were going
to get a little (specimen) from that tissue and that’s
it. [Participant 4]
It was basically that they took extra blood from me,
at the time when they were taking blood before the
chemo. Also just talking about what side effects you
would have and how you feel. [Participant 5]
What are the patient-reported effects of research
participation?
Participation in research was seen as inherently positive
and beneficial by some patients who chose to attend a
teaching hospital so that they could potentially be
involved in research.
One of the things that appealed to me, of course my
main reasons why I wanted to be at a teaching hos-
pital is to be involved in possibly, this or that trial
[Participant 6]
Women described a range of benefits that varied with
the type of research in which they participated. For the
women assigned to the intervention arm of a trial compar-
ing 1 week of radiotherapy to the standard 3, the main
benefit they described was having a shortened duration of
treatment.
I was fully informed by the woman who was organ-
ising the trial or administrating it, of potential side
effects. . . then I weighed that up against having
three weeks’ worth of radiotherapy, which I had sort
of pretty much decided “No way, thank you!” [Par-
ticipant 6]
Another benefit identified by patients was access to
additional monitoring. One woman who took part in a
study of the effects of chemotherapy on the heart felt the
regular echocardiograms were beneficial, not just for pro-
viding checks on her cardiovascular health, but also
because they made her more conscious of maintaining a
healthy lifestyle in general. However, the additional moni-
toring was not without disadvantages as she also found
herself feeling anxious and inferring the worst from clini-
cians’ actions during the monitoring procedures.
So, I have my echoes, but every time I go, that’s
another thing. I go and they do you on that
machine. They make one little noise, I say, “What,
have you seen something?” They say, “No, we’re
just checking” . . . They said my heart is fine, but
that makes you eat healthier. I’ve been eating much
more healthily. [Participant 7]
The woman who had donated bone marrow every
6 months over a 7-year period described how participating
in research had affected her relationship with her oncolo-
gist, who was also running the study. Years after the study
had been completed, her arthritis was aggravated intolera-
bly by the hormonal cancer treatment she was undergoing.
While other doctors dismissed her complaints and felt she
should continue with the treatment regardless, she felt
that the personal relationship she had built with her
oncologist meant that he listened to her complaints seri-
ously and took steps to adjust her treatment so as to
improve her quality of life.
I was under his trial for 7 years to-ing and fro-ing
and I put myself out in lots of different ways and I
used to see a lot of him. I think he knew that I
wasn’t making a fuss. [Participant 8]
A good relationship with staff meant one woman
enrolled in a trial did not have to wait to have her routine
pre-chemotherapy blood tests done; instead these were
done by the research nurse at the same time as the trial
samples were being collected.
They cut a few corners for me every now and again.
The blood tests, I always have them done anyway.
So what [the research nurse] did was, she did them
herself, so I didn’t have to go down to the phlebot-
omy and have it done there. So I sort of gained a lit-
tle bit on that really, because she did the whole lot
in one go. [Participant 9]
Among the women who took part in studies that did not
involve ongoing monitoring or a change in their treatment
plan, the reported effects of their participation in research
were more abstract; for example, the women who had
taken part in interviews or surveys felt glad to have the
opportunity to express their opinions or tell their story.
There was also a sense of pride among the women who
had participated in research and a feeling that they were
helping others. This was especially clear in one case where
the drug a woman had trialled subsequently became stan-
dard treatment. A young woman who donated tissue sam-
ples for genetic research also gained comfort from her
belief that, if the research team made any breakthroughs
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or discoveries, she may potentially benefit herself in the
future from improved treatments and therapies specific to
her tumour type.
Because if you don’t have people doing trials then
they can’t do the research properly, can they, and
then you can’t get better treatment. [Participant 5]
If it’s going to help other people, why not? I’m not
selfish. . . It’s for helping others; I don’t mind. [Par-
ticipant 4]
I did my five years on Arimidex. Thanks to me . . .
and thousands of others it got its licence. So by the
time I was . . . finished all my other treatments, Ar-
imidex was top of the list. [Participant 10]
DISCUSSION
To the authors’ knowledge, this is the first large study to
explore the effects of research participation on cancer
patient experience using quantitative and qualitative data
sources. As hypothesised, patients who took part in cancer
research reported a more positive patient experience.
Patients who participated in research were more likely
than those who did not to describe their overall care and
treatment as very good or excellent and to rate all of the a
priori aspects of patient experience in our conceptual
model positively. For example, research participants had
more positive interactions with staff, better coordination
of care and were more likely to feel that they were treated
as individuals. However, there was no common under-
standing of what constitutes cancer research, and no clear
delineation between research participation and standard
care, from the patient perspective.
A strength of this study is that it analyses data from a
large, national sample of cancer patients and is not lim-
ited to patients with poor prognoses. Furthermore, the
interview data provide insight into patients’ understand-
ing of what constitutes cancer research and how research
participation affects their experience (though as inter-
views were limited to breast cancer patients, these find-
ings may not be generalisable to the entire patient
population). The other main limitations of this study
relate to potential biases in the data which may also
affect the generalisability of our study findings. For
example, ethnic minorities and young patients are
known to be less likely to respond to NCPES and are
therefore under-represented in the quantitative data set
analysed in this study. Ethnic minorities were also
under-represented in the interview sample due to the
approach used for recruitment. Furthermore, negative
aspects of research participation may have been under-
reported by participants as interviewers did not specifi-
cally prompt on this topic.
The positive effect of research participation on relation-
ships with staff was evident in both NCPES responses and
our interviews. The more positive interactions with staff
associated with participation may be due to the time and
attention staff had for patients as a result of their
involvement in research, benefits that have been reported
elsewhere (Maslin-Prothero 2000; Hussain-Gambles et al.
2004). The quality of relationships that research staff and
participants were able to develop may explain why
research participants were more likely to report feeling
that they were treated as individuals by staff. In NCPES
data, participants were more likely to have been asked
what name they preferred to be called and to have their
views taken into account when deciding on treatment and
patients also described better relationships with staff in
the interviews. In particular, the woman who had been
involved in a 7-year trial described how her participation
enabled her oncologist to get to know her as an individual.
The effects of this relationship were evident years after
her involvement in research, influenced subsequent treat-
ment decisions and improved her quality of life. Access to
non-standard care and treatment was one of the benefits of
research participation evident from analysis of NCPES
data, with participants more likely to have access to spe-
cialist staff such as dieticians. In our patient interviews,
the effects of research participation on access to non-stan-
dard care and treatment were also evident though they
often remained implicit in patients’ descriptions of their
care and treatment overall. For example, some patients
described how taking part in a trial allowed them to have a
shorter than standard duration of radiotherapy, something
they would have preferred ordinarily if the choice had
been available. Taking part in a study (even one that
involved randomisation) provided patients with the oppor-
tunity to influence their treatment plan.
From the NCPES data, patients who took part in
research were more likely to have been better informed by
staff about some elements of their care and treatment (spe-
cifically tests) and to feel that they received the right
amount of information about their condition and treat-
ment overall, perhaps because staff were more likely to
view participants as individuals or partners and therefore
to make greater efforts to listen and explain carefully
when dealing with them. It is also possible that patients
participating in research felt more empowered to ask ques-
tions and seek information about their care and treatment.
Research participants also benefited from better coordina-
tion of care, which may be attributable to closer follow-up
or better organisation of care within a research study (Catt
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et al. 2011). There was nomention of having better coordi-
nation of care or receiving more information about their
condition in our interviews. However, the open approach
taken in our in-depth interviews may have contributed to
the narrow range of effects described by patients as women
were not prompted to comment on any specific effects of
research participation. This methodology contrasts with
many other studies that are survey or questionnaire-based,
where patients are asked to select from, rank or rate pre-
specified items, a procedure that introduces its own bias.
The limited descriptions of the effects of research can also
be attributed to the fact that there was no common under-
standing of what constitutes cancer research among the
women we interviewed; for example, one woman assigned
to the control arm of a trial did not think she had partici-
pated in research and while most women who participated
in our interview study considered this to be ‘cancer
research’, one woman did not. There was also no clear
delineation between research participation and standard
care and treatment from the patients’ perspective as the
research reported often took place in the same location as
standard treatment and involved the same staff. One
woman was unsure if she had participated in research or
not, which is not uncommon among cancer patients (Joffe
et al. 2001). It is unsurprising therefore that it was diffi-
cult for patients to describe the effects of research partici-
pation when they could not readily identify it or
disentangle it from their normal care.
National Cancer Patient Experience Survey does not ask
about motivations for participating in cancer research,
something which was explored in our interviews. Being
able to help others was the most frequently mentioned
effect of research participation and was also a strong moti-
vator to take part in a study. This desire to affect other
patients in a positive way through involvement in
research is often labelled altruism (Catt et al. 2011). It is
more common among patients with good prognoses, such
as the majority of women that we interviewed, and some
have argued that this is because they are well enough to
think beyond their own personal situations (Hallowell
et al. 2010). However, when thinking about helping oth-
ers, the nature of cancer as a potentially recurrent or life-
long illness with strong familial and genetic elements
must also be considered. In a context where the possibility
of future illness threatens women who have been treated
for cancer, as well as their close family members, this
desire to help others could also be viewed as a form of car-
ing. By participating in research trials, cancer patients are
hoping to improve care and treatment for future patients,
who may include themselves or their relatives.
Analysis of both quantitative and qualitative data
sources suggests that taking part in research is beneficial
to patient experience with participants rating their care
more positively. While the effects of taking part in
research varied with the nature of the study, they did not
appear to be limited to patients involved in clinical trials,
those who took part in interviews or made one-off dona-
tions of samples also appeared to benefit. The more posi-
tive patient experience evident in our study may be due to
inherent differences among those who participate in
research, with those who choose to take part being opti-
mists (Agrawal et al. 2006) and therefore more likely to
rate their experiences positively. However, it may also be
due to differences in the provision of care and treatment
experienced by patients as a result of being involved in
cancer research. Further work to explore how participation
positively affects patient experience would be useful to
develop strategies aimed at improving care and treatment
for all patients, regardless of whether or not they choose or
have the opportunity to take part in research.
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